What ICD‑10‑CM code should be used when ordering a prostate‑specific antigen (PSA) test?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

ICD-10 Code for PSA Testing

For ordering a PSA test, use ICD-10 code Z12.5 (Encounter for screening for malignant neoplasm of prostate) for asymptomatic screening, or R97.20 (Elevated prostate specific antigen [PSA]) for follow-up of abnormal results.

Primary Screening Codes

When ordering PSA testing for prostate cancer screening in asymptomatic men, the appropriate code is:

  • Z12.5: Encounter for screening for malignant neoplasm of prostate

This code should be used when:

  • The patient has no symptoms of prostate disease
  • No prior diagnosis of prostate cancer exists
  • The test is being performed as part of routine screening per guideline recommendations 1, 2

Alternative Diagnostic Codes

For non-screening scenarios, consider these codes:

  • R97.20: Elevated prostate specific antigen (PSA) - use for follow-up of previously elevated PSA
  • N40.0: Benign prostatic hyperplasia without lower urinary tract symptoms - if ordering PSA for BPH monitoring
  • N40.1: Benign prostatic hyperplasia with lower urinary tract symptoms - if patient has obstructive urinary symptoms
  • Z85.46: Personal history of malignant neoplasm of prostate - for surveillance after prostate cancer treatment

Clinical Context for Code Selection

Research demonstrates that PSA tests fall into distinct categories that should guide your coding choice 3:

  • Pure screening (19% of tests): Asymptomatic patients with no urinary symptoms → use Z12.5
  • Symptomatic screening (46% of tests): Patients with obstructive urinary symptoms → use N40.1 or N40.0
  • Diagnostic testing (35% of tests): Follow-up of abnormal results or known disease → use R97.20 or other specific codes

Important Coding Pitfalls

Avoid using symptom codes when performing true screening, as this may:

  • Affect insurance coverage and reimbursement
  • Misrepresent the clinical indication
  • Impact quality metrics and screening statistics

Do not use Z12.5 if the patient has:

  • Current urinary symptoms (use symptom-specific codes)
  • Known prostate cancer (use Z85.46 for surveillance)
  • Previously elevated PSA requiring follow-up (use R97.20)

Screening Guidelines Context

Current evidence shows PSA screening likely reduces prostate cancer-specific mortality (Rate Ratio 0.87,95% CI 0.80-0.95) 4, supporting the use of screening codes in appropriate populations. Guidelines recommend shared decision-making for men ages 55-69 years 2, with consideration for earlier screening in high-risk populations including African American men and those with family history 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.